<!DOCTYPE html><html><head><link href='https://fonts.googleapis.com/css?family=Spectral' rel='stylesheet'><style>body {    font-family: 'Spectral';font-size: 14px;}</style></head><body><b>Search Term: </b>("sickle cell disease" OR "beta thalassemia") AND ("gene therapy" OR "genome editing" OR "mRNA therapy")<br><b>Date run: </b>2020/01/02<br><br><h2>PubMed Articles</h2> <br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31822676">Monkeys mutant for PKD1 recapitulate human autosomal dominant polycystic kidney disease.</a></b><br><b>Journal:</b> Nat Commun<br><b>Two-year IF:</b> 11.80<br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31578323">Development of a forward-oriented therapeutic lentiviral vector for hemoglobin disorders.</a></b><br><b>Journal:</b> Nat Commun<br><b>Two-year IF:</b> 11.80<br><br><b><a href="https://ncbi.nlm.nih.gov/pubmed/31492863">Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I.</a></b><br><b>Journal:</b> Nat Commun<br><b>Two-year IF:</b> 11.80<br><br><b><a href="http://google.com">More Results...</a></b><br><br><h2>Companies</h2> <br><br><b><a href="https://www.linkedin.com/company/crispr-therapeutics/about/">CRISPR Therapeutics</a></b><br><br><b><a href="https://www.linkedin.com/company/orchard-therapeutics/about/">Orchard Therapeutics</a></b><br><br><b><a href="https://www.linkedin.com/company/trucode-gene-repair-inc/about/">Trucode Gene Repair, Inc.</a></b><br><br><b><a href="http://google.com">More Results...</a></b><br><br><h2>Patents</h2> <br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=1&p=1&f=G&l=50&d=PTXT&S1=((%22sickle+cell+disease%22+OR+%22beta+thalassemia%22)+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS=+("sickle+cell+disease"+OR+"beta+thalassemia")+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=(("sickle+cell+disease"+OR+"beta+thalassemia")+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription</a></b><br><b>Patent date:</b> December 31, 2019<br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=2&p=1&f=G&l=50&d=PTXT&S1=((%22sickle+cell+disease%22+OR+%22beta+thalassemia%22)+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS=+("sickle+cell+disease"+OR+"beta+thalassemia")+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=(("sickle+cell+disease"+OR+"beta+thalassemia")+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">Highly efficient NRF2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation</a></b><br><b>Patent date:</b> December 31, 2019<br><br><b><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=3&p=1&f=G&l=50&d=PTXT&S1=((%22sickle+cell+disease%22+OR+%22beta+thalassemia%22)+AND+((%22gene+therapy%22+OR+%22genome+editing%22)+OR+%22mRNA+therapy%22))&OS=+("sickle+cell+disease"+OR+"beta+thalassemia")+AND+("gene+therapy"+OR+"genome+editing"+OR+"mRNA+therapy")&RS=(("sickle+cell+disease"+OR+"beta+thalassemia")+AND+(("gene+therapy"+OR+"genome+editing")+OR+"mRNA+therapy"))">3-oxa-8-azabicyclo[3.2.1]octane derivatives and their use in the treatment of cancer and hemoglobinopathies</a></b><br><b>Patent date:</b> December 31, 2019<br><br><b><a href="http://google.com">More Results...</a></b><br><br><br><b><a href="http://google.com">Link to Full Search Results</a></b><br><body><html>